President Trump signed an executive order on Thursday aimed at cutting through the red tape of federal drug policy, officially directing the attorney general to expedite moving marijuana from the highly restrictive Schedule I tier to Schedule III.
The directive picks up the baton on a regulatory shift initiated under the Biden administration but left unfinished before the transfer of power. While the political leadership has changed, the momentum has not; Trump had signaled back in August that he was open to seeing the process through.
The administration frames the move as a “commonsense approach” driven strictly by science and medicine rather than recreational legalization. A senior administration official emphasized that the primary goal is unlocking barriers to research.
READ: FEDS: California Doctor Billed Medicare $45M For Botox While Patients Were In Prison
“The executive order the President will sign today is focused on increasing medical research for medical marijuana and CBD,” the official said during a press briefing. “The president is very focused on the potential medical benefits… [and] has directed a commonsense approach that will automatically start working to improve the medical marijuana and CBD research to better inform patients and doctors.”
Breaking Down the Schedules
Under the Controlled Substances Act, Schedule I drugs—where marijuana currently sits alongside heroin and LSD—are defined as having “no currently accepted medical use.” Moving it to Schedule III acknowledges a medical utility and categorizes the substance as having a “moderate to low potential” for dependence.
Administration officials pointed to a 2023 Department of Health and Human Services review to back up the shift. That data showed that over 30,000 health care practitioners nationwide have recommended medical marijuana to more than 6 million registered patients for at least 15 different medical conditions.
Business Implications and the Banking Reality
READ: Former VP Kamala Harris Defends Keeping Distance From Epstein Files As Release Deadline Looms
While the executive order does not touch criminal penalties or legalize recreational use, the economic implications for the cannabis industry are massive. Reclassification to Schedule III would allow marijuana businesses to finally deduct standard business expenses from their federal taxes—a practice currently banned for those dealing in Schedule I or II substances.
However, experts warn that reclassification isn’t a magic wand for the industry’s banking woes. Kevin Hart, Founder and CEO of Green Check, noted that moving the drug down the scheduling list might actually complicate the regulatory landscape before it simplifies it.
“Rescheduling won’t simply give banking a green light,” Hart said. “In fact, it will usher in new and likely more complex rules and regulatory expectations for both cannabis businesses and financial institutions.”
Hart added that with multiple federal agencies likely stepping in to manage the new status, oversight will increase. “The ability to connect these requirements across every point where plant and money movement intersect will become absolutely essential.”
For now, the White House remains tight-lipped on whether the President is considering any future moves regarding recreational use, keeping the focus strictly on medical research and tax relief for the existing industry.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
